Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1800 Bridge Parkway REDWOOD CITY CA 94065 |
Tel: | N/A |
Website: | https://www.nevro.com |
IR: | See website |
Key People | ||
D. Keith Grossman Executive Chairman of the Board | Greg Siller Senior Vice President, Chief Commercial Officer | Kevin R. Thornal President, Chief Executive Officer, Director |
Roderick H. Macleod Chief Financial Officer, Senior Vice President | Lori Ciano Chief Human Resource Officer, Senior Vice President | Kashif Rashid Senior Vice President, General Counsel, Company Secretary |
David Caraway Senior Vice President, Chief Medical Officer | Christopher Christoforou Senior Vice President - Technical Operations | Donald A. Middlebrook Senior Vice President - Clinical, Regulatory and Quality | Jon R. Shear Senior Vice President - Corporate Development |
Business Overview |
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead. |
Financial Overview |
For the fiscal year ended 31 December 2023, Nevro Corp revenues increased 5% to $425.2M. Net loss totaled $92.2M vs. income of $3M. Revenues reflect United States segment increase of 5% to $366.6M, International segment increase of 1% to $58.6M. Net loss reflects Certain litigation charges decrease from $105M (income) to $0K, Selling/General/Admin. Expense - Balanci increase of 5% to $290.2M (expense). |
Employees: | 1,215 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $331.49M as of Dec 31, 2023 |
Annual revenue (TTM): | $425.17M as of Dec 31, 2023 |
EBITDA (TTM): | -$90.16M as of Dec 31, 2023 |
Net annual income (TTM): | -$92.21M as of Dec 31, 2023 |
Free cash flow (TTM): | -$67.42M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 36,681,392 as of Mar 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |